Table 1: Clinicopathological characteristics of the study population.

ParametersMaleFemaleOverall

Number of patients24155179
Age of diagnosis of primary biliary cirrhosis (years)*55.5 (22–75)57 (24–85)57 (22–85)
Duration of follow-up (months)*†96.5 (27–218)97 (12–281)97 (12–281)
Number of patients with Scheuer's stage (I/II/III/IV)13/5/2/488/37/17/13101/42/19/17
Brinkman index*400 (0–1575)0 (0–940)0 (0–1575)
Number of patients with a history of blood transfusion32023
Number of patients with a history of drinking4711
Number of symptomatic patients44953
 Pruritus13637
 Jaundice279
 Ascites033
 Varices21517
Biochemical data
 AST (IU/L)*59.5 (26–140)46.5 (16–258)49 (16–258)
 ALT (IU/L)*72 (17–233)41 (10–329)46 (10–329)
 ALP (lU/L)*652 (94–2113)501.5 (112–2985)535.5 (94–2985)
γ-GTP (IU/L)*350.5 (75–1349)164 (13–1004)173.5 (13–1349)
 Alb (g/dL)*4.2 (2.4–5.1)4.2 (1.9–5.0)4.2 (1.9–5.1)
 T-Bil (mg/dL)*0.8 (0.3–3.9)0.7 (0.1–6.3)0.7 (0.1–6.3)
 IgG (mg/dL)*1660 (1194–3092)1676 (778–4532)1660 (778–4532)
 IgM (mg/dL)*482 (72–1465)346 (48–1660)352.5 (48–1660)
 Plt ( 104/ L)*24.4 (8.7–58.1)20.7 (5.3–48.6)20.9 (5.3–58.1)
 PT (%)*105.0 (78.0–126.5)100.0 (44.0–139.0)100.0 (44.0–139.0)
Number of patients with medications (UDCA/BF/UDCA + BF/none)17/0/7/0127/1/22/5144/1/29/5
Number of deaths during follow-up42731

*Data expressed as median (range); Data include first year of follow-up.; Alb: albumin; ALP: alkaline phosphatase; ALT: alanine aminotransferase; AST: aspartate aminotransferase; BF: bezafibrate; -GTP: -glutamyltranspeptidase; Plt: platelet; PT: prothrombin time; T-Bil: total bilirubin; UDCA: ursodeoxycholic acid.